The strong beat and raised guidance, combined with the $100M buyback authorization, signal accelerating Rare Disease momentum and management confidence. Watch for Cortrophin Gel growth trajectory and the acute gouty arthritis sales force deployment in mid-2026 as key catalysts.
ANIP drugs
ANIP drug pipeline →Price Chart
Executive Summary
ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M (+20.5% YoY) and GAAP diluted EPS of $1.28, beating consensus estimates of $207.6M and $1.30. The company raised full-year 2026 guidance across revenue, adjusted EBITDA, and adjusted EPS, and authorized a $100M share repurchase program through 2029.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $237.5M, +20.5% YoY vs $197.1M
- GAAP diluted EPS $1.28 vs $0.69 YoY
- Adjusted non-GAAP diluted EPS $2.05 vs $1.70 YoY
- Adjusted non-GAAP EBITDA $63.0M, +24.1% YoY
- Cortrophin Gel revenue $75.1M, +42.1% YoY
- ILUVIEN revenue $19.3M, +19.5% YoY
- Generics revenue $105.4M, +6.8% YoY
- Raised FY2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B)
- Raised FY2026 adjusted EBITDA guidance to $285M-$300M (from $275M-$290M)
- Raised FY2026 adjusted diluted EPS guidance to $9.19-$9.69 (from $8.83-$9.34)
- Authorized $100M share repurchase program through May 2029
- Cash and cash equivalents $311.2M as of March 31, 2026
- Operating cash flow $58.4M in Q1 2026
Financial Impact
Revenue beat consensus by ~$30M (14.4%), EPS beat by $0.75 (57.7% on GAAP basis vs $1.30 consensus). Guidance raised across all key metrics.
Risk Factors
- Brands revenue declined 50.9% YoY due to demand normalization
- Gross margin contracted ~230bps YoY (GAAP) due to royalty-bearing product mix
- Reliance on single-source third-party manufacturing for Cortrophin Gel and ILUVIEN
- Insurance re-verification seasonality may impact Cortrophin Gel in future quarters
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000049 |
| Document: ani-20260508.htm | 0001023024-26-000049 |
| Document: 0001023024-26-000049-index-headers.html | 0001023024-26-000049 |
| Document: 0001023024-26-000049-index.html | 0001023024-26-000049 |
| Document: 0001023024-26-000049.txt | 0001023024-26-000049 |
| 8-K Data (Synthetic) | 0001023024-26-000049 |
Track record
34 reports on ANIP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers